Microplastics as both a driver of genitourinary cancers and a deliverer of treatments
Abstract
Microplastics and nanoplastics (MNPs) are environmental contaminants increasingly detected in human tissues, raising public health concerns. Although evidence is still insufficient to directly link MNPs to genitourinary cancers (GU), this Review examines their potential role in prostate, bladder, and renal cell carcinoma. Proposed mechanisms include chronic inflammation, oxidative stress, genotoxicity, and endocrine disruption driven by plastic-associated additives. Emerging studies report quantitative detection of MNPs within human prostate and bladder tumors, with higher burdens associated with dietary habits such as frequent take-out food consumption. The Review also highlights their role in cancer therapy: MNPs may alter antineoplastic drug pharmacokinetics and promote resistance, yet polymer-based nanoparticles can be engineered as advanced drug delivery platforms. Materials such as PLGA and PEG may improve targeted delivery of chemotherapies and immunotherapies, supporting more effective and personalized treatment strategies in GU oncology.
Read the paper
Related studies
- Green Chemistry: A Framework for a Sustainable Future
- Nano/micro-plastic, an invisible threat getting into the brain
- Emerging contaminants antibiotic resistance genes and microplastics in the environment: Introduction to 21 review articles published in CREST during 2018–2022
- Water Resources and Sustainable Development
- Nano- and microplastics in the workplace
- Water Enclosure and World-Literature: New Perspectives on Hydro-Power and World-Ecology
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.